Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada
today announced new collaborations with two Canadian early-stage drug
technology development centers, Montreal-based NEOMED and Toronto-based
MaRS Innovation, to identify and advance promising bio/pharmaceutical
technologies that have the potential to impact human health.
Through these collaborations, technical experts from the Johnson &
Johnson Innovation Center in Boston, Massachusetts will work with NEOMED
and MaRS Innovation to identify investment opportunities emerging from
well-validated scientific research discoveries within their communities
of academic institutions and biotechnology companies.
"We know from our history of engagement that the Canadian
bio/pharmaceutical environment is one of the most vibrant in the world,"
said Robert Urban, Head of the Johnson & Johnson Innovation Center,
Boston. "These new collaborations will allow us to potentially advance
important new clinical candidates against disease."
"Quebec and Ontario are home to numerous world-class academic and
biomedical research enterprises," said Paul Kershaw, Vice President of
Medical Affairs, Janssen Inc. in Canada. "These new relationships with
NEOMED and MaRS Innovation are an extension of our commitment to
Canada's innovative research community."
NEOMED is a not-for-profit, public-private Pharma alliance dedicated to
drug discovery and development. Partially funded by the Ministère des
Finances et de l'Économie du Québec, NEOMED is within the NEOMED
Institute, a state-of-the-art R&D facility in the Montréal Technoparc.
MaRS Innovation is the commercialization agent for Ontario's discovery
pipeline from 16 leading academic institutions. MaRS Innovation is
supported by the Government of Canada through the Networks of Centres of
Excellence, by the Government of Ontario through the Ontario Centres of
Excellence, and by its 16 member institutions.
About Johnson & Johnson Innovation
The Boston Innovation Center is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Corporation. Johnson & Johnson
Innovation focuses on accelerating early innovation and enhancing
opportunities for collaboration and investment across Johnson &
Johnson's global healthcare businesses. Johnson & Johnson Innovation
provides scientists, entrepreneurs and emerging companies focused on
early-stage opportunities a one-stop access to science and technology
experts who can facilitate collaborations across the pharmaceutical,
medical device and diagnostics and consumer companies of Johnson &
Johnson. Johnson & Johnson Innovation includes local deal-making
capabilities with the flexibility to adapt deal structures to match
early-stage opportunities and establish novel collaborations that speed
development of those innovations to solve unmet needs in patients.
Follow us @jnjinnovation on Twitter. Please visit www.jnjinnovation.com
for more information.
About Janssen Inc.
Janssen is dedicated to addressing and solving some of the most
important unmet medical needs of our time in oncology, immunology,
neuroscience, infectious diseases and vaccines, metabolic and chronic
diseases and women's health. Driven by our commitment to patients, we
bring innovative products, services and solutions to people throughout
the world. Janssen Inc. in Canada is part of the Janssen Pharmaceutical
Companies of Johnson & Johnson. Please visit http://www.janssen.ca
for more information.
Johnson & Johnson
John Lacey, 781-392-5514
Jessica Rowlands, 202-729-4089